Expediting the Development of Patient-Specific iSPC Cell Therapies

Video

Stefan Braam, PhD, chief executive officer of Ncardia and Cellistic discussed the companies’ work in the cell therapy space.

“We make induced pluripotent stem cells (iPSCs), we differentiate them to target cells, such as heart muscle cells, or neurons. We manufacture those cells at scale and work with therapeutic developers to build the most relevant human biology. We can start with a patient with heart failure, or patient with a with a neurological disease, make IPSCs that are truly patient specific and use that in drug discovery to accurately predict whether a drug is going to be safe and effective for that patient population.”

Ncardia is a a company working in contract research, development and manufacture of iPSC-based solutions for early and preclinical drug discovery, with a focus on cardiovascular and neural cells. Its goal is to enable pharmaceutical and therapeutics companies to make more confident decisions in discovery and development by integrating iPSC technologies into their screening processes. The company works with others to research, development and manufacture  human induced pluripotent stem cell (iPSC)-based therapies early and preclinical drug discovery.

In April 2022, Ncardia launched Cellistic, a company focused on iPSC-based process development and manufacturing, to leverage Ncardia’s scientific and technical knowledge for cell therapy development. Cellistic is building proprietary manufacturing platforms that can deliver iPSC-based immune cells at scale.

CGTLive spoke with Stefan Braam, PhD, chief executive officer of Ncardia and Cellistic, to learn more about the companies and their work in the drug discovery and cell therapy space. He also discussed possible future avenues for cell therapy.

REFERENCE
Ncardia launches Cellistic, an iPSC cell therapy CDMO. News release. Ncardia. April 14, 2022. https://www.ncardia.com/news/press-release-ncardia-launches-cellistic

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.